Scinovex
article Open AccessTop 1% cited

Intravitreal triamcinolone acetonide for exudative age related macular degeneration

British Journal of Ophthalmology · 2003 · Vol. 87(4) · pp. 462–468
Jost B. Jonas

Abstract

Intravitreal injection of 25 mg of crystalline triamcinolone acetonide merits further study for the treatment of exudative age related macular degeneration.

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s SyndromeGlaucoma and retinal disordersMedicineTriamcinolone acetonideVisual acuityOphthalmologyIntraocular pressureAcetonideMacular degenerationRetinal detachmentEndophthalmitisRetinal

MeSH terms

AgedAged, 80 and overCataractFemaleGlucocorticoidsHumansInjectionsIntraocular PressureMacular DegenerationMaleMiddle AgedProspective StudiesTime FactorsTriamcinolone AcetonideVisual Acuity
Citations
496
FWCI
81.29
field-weighted impact
References
60
Percentile
100%
vs. same field & year
Citations per year
Cited by
Macrophage Depletion Diminishes Lesion Size and Severity in Experimental Choroidal Neovascularization
Investigative Ophthalmology & Visual Science · 2003 · 411 citations
Intravitreal triamcinolone acetonide for exudative age related macular degeneration
British Journal of Ophthalmology · 2003 · 496 citations
Intraocular pressure after intravitreal injection of triamcinolone acetonide
British Journal of Ophthalmology · 2002 · 424 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.